TrialLeukemia2017
IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).
J Krönke et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
26 papers cite it
this papertrialcites it